Abobotulinumtoxina
As of the edition of 20 October 2026, Abobotulinumtoxina is a drug: marketed, first approved in 2009 (US); acts on SNAP25; US protection ended in 2023.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Unknown
- Brand name
- Dysport
- First approved
- 29 April 2009 (US)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Ipsen
- Registered trials
- 24, 2 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Skin and connective tissue; Cancer; Heart and blood vessels; Inherited and neonatal
US protection
US protection ended in 2023.
The orphan exclusivity ended in 2023 (it covers one use only). The application that gives this date is held by Ipsen.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SNAP25 | Synaptosomal-associated protein 25 | P60880 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 3 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 4 | 3 | 0 | 0 |
| Phase 4 | 12 | 6 | 3 | 2 |
| All trials | 24 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ipsen | Applicant | 2009 to now |